Diligence memo · auto-generated · as of July 3, 2026

Stratum Biosciences Inc.

Stratum Biosciences Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 5.5× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Stratum Biosciences Inc. operates in Biotech / Pharma, based in MADISON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Stratum Biosciences Inc. has raised $650K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $550K on 2025-12-10.

Most recent recorded round closed around 2025-12-10.

Valuation (modeled)modeled

Provath models Stratum Biosciences Inc. at approximately $1.1M (range $301K–$2.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.25× the median modeled value of Pre-Seed Biotech / Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 26 months.

Last raise 7 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 5.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 26% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 10% of those peers.

Closest niche peers: Cosmos Pharmaceuticals, LLC, Amptiv Biosciences, Inc., Fairfield Bio, Inc., Gaingels Aether Bio 2025 LLC, Gaingels Glyphic Bio 2025 LLC.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.